Patheon Completes Sterile Expansion Project at Greenville, NC Manufacturing Site
08 May 2017 - 8:30PM
Business Wire
Company Invests $26 million in Sterile PDS
Suite
Patheon N.V (NYSE: PTHN), a leading global provider of
high-quality drug development and delivery solutions to the
pharmaceutical and biopharma sectors, announced that it has
completed an expansion project at its Greenville, NC manufacturing
site. The company invested approximately $26 million to update one
of its sterile Pharmaceutical Development Services (PDS) suites and
to build a state-of-the-art, fully integrated sterile PDS suite
which are compliant with regulatory authorities. The PDS Suites 1
and 2 provide 7,000-square-feet in GMP steriles manufacturing
space.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170508005315/en/
Aerial shot of Patheon's Greenville, NC
manufacturing facility (Photo: Business Wire)
The newly built PDS suite will manufacture sterile liquid and
lyophilized drug products. It features freeze dryers and a fully
integrated filling line fitted with a Restricted Access Barrier
System (RABS) for sterile drug products. The company has made the
investment in disposable manufacturing in this suite eliminating
the need for cleaning verification for liquid filling, reducing set
up time/product losses and enhancing sterility assurance. This
suite is highly sophisticated, fully integrated and designed for
products in clinical development with the ability to scale up to
much larger batch sizes via Patheon’s network of commercial scale
capabilities either co-existing within the Greenville facility, or
in Europe.
“As the industry continues to innovate, customers will require
even more advanced solutions, integrating development and
commercial service, to meet their business needs,” said Franco
Negron, president of Patheon’s drug product and pharmaceutical
development services for North America. “The increasing focus on
pharma to reduce costs will lead forward-thinking companies to
capitalize on their core competencies – focusing on what they do
best, while strategically partnering with companies such as Patheon
to deliver the expertise, customized solutions and technical
capabilities to support the production of their small and large
molecule products.”
Patheon’s Greenville, NC manufacturing site is a large
multi-purpose pharmaceutical manufacturing and packaging campus.
The facility provides both solid dose form manufacturing/packaging
and sterile dose manufacturing, filling and lyophilization of both
biopharmaceuticals and small molecules. Another exciting
development in Greenville, NC is the installation of a state of the
art continuous manufacturing suite.
About PatheonPatheon is a leading global provider of
pharmaceutical development and manufacturing services. With
approximately 9,100 employees and contractors worldwide, Patheon
provides a comprehensive, integrated and highly customizable set of
solutions to help clients of all sizes satisfy complex development
and manufacturing needs at any stage of the pharmaceutical
development cycle. A Healthier World. Delivered.
www.patheon.com
Editors’ Notes: Glossary of Terms
Aseptic processing is the process by which a sterile
(aseptic) product (a pharmaceutical) is packaged in a sterile
container in a way that maintains sterility.
Freeze-drying—technically known as lyophilisation,
lyophilization, or cryodesiccation—is a dehydration
process typically used to preserve a perishable material or make
the material more convenient for transport. Freeze-drying works by
freezing the material and then reducing the surrounding pressure to
allow the frozen water in the material to sublimate directly from
the solid phase to the gas phase.
cGMP Facility: cGMP refers to current Good Manufacturing
Practices, a rigorous set of manufacturing guidelines the U.S Food
and Drug Administration (FDA) uses to document and ensure the
products it regulates are produced safely and consistently.
Sublimation is the transition of a substance directly
from the solid to the gas phase without passing through the
intermediate liquid phase.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170508005315/en/
PatheonMari Mansfield, 919-226-3137Senior Director, External
CommunicationsMari.Mansfield@Patheon.commedia@patheon.com
PATHEON N.V. (NYSE:PTHN)
Historical Stock Chart
From Oct 2024 to Nov 2024
PATHEON N.V. (NYSE:PTHN)
Historical Stock Chart
From Nov 2023 to Nov 2024